Back

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Cardiomyopathies: present and future Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Maria Rita Lima

Hospital Santa Cruz, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
DPD quantification correlates with ECV and disease severity in transthyretin cardiac amyloidosis
Doctor R. Rettl (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
ATTRibute-CM: ITT sensitivity analysis and sub-analysis comparing acoramidis and placebo in stage 4 CKD
Professor S. Poulsen (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Temporality of events leading to the diagnosis of obstructive hypertrophic cardiomyopathy (oHCM): a machine learning approach using UK retrospective data
Mr M. Hurst (Cardiff, GB)
Abstract Slides Video
Presentation thumbnail
Delayed diagnosis of hypertrophic cardiomyopathy: results from electronic medical records analysis
Doctor C. Mao (San Francisco, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiomyopathies: present and future
Video

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources